#CSBR hashtag - Bluesky

PenkeTrading

@penkeinvesting.bsky.social

1 week ago

Fundamental analysis of $CSBR (CHAMPIONS ONCOLOGY, INC.) based on financial data and reported results.

#CSBR

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 weeks ago

#CSBR #167968a9-3f60-4071-a093-e87cedd52a9b #earningscall-transcripts

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Champions Oncology Reports Revenue of $16.6 Million Champions Oncology (Nasdaq:CSBR) reported Q3 fiscal 2026 total revenue of $16.6 million (record study service revenue, +32% year-over-year excluding a prior $4.5M data license). Adjusted EBITDA was $574,000 and GAAP loss from operations was about $276,000. Cash was approximately $7.1 million with no debt.Costs and operating expenses rose 34.3% year-over-year, driven by outsourced lab services and investments in the data platform and commercial team; management expects margin improvement as radiolabeling moves in-house.

#CSBR Champions Oncology Reports Revenue of $16.6 Million

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million Champions Oncology (Nasdaq:CSBR) reported record quarterly service revenue of $15.0 million for Q2 FY2026 (period ended Oct 31, 2025), up 11.5% year‑over‑year, and oncology services profit of $7.8 million with a margin of 52% (vs 45% prior year). Adjusted EBITDA was $843,000 and net income was $237,000 for the quarter. Year‑to‑date revenue was $29.0 million (+5.4%) with adjusted EBITDA of $962,000. Cash on hand was approximately $8.5 million and the company reported no debt. Management emphasized investment in its data platform and targeted sales/IT hires while expecting positive adjusted EBITDA for the full fiscal year.

#CSBR Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Oncology Research Leader Champions Reports $14M Revenue as New CEO Rob Brainin Charts Growth Strategy Champions Oncology delivers $14M Q1 FY2026 revenue with $60K adjusted EBITDA. New CEO Rob Brainin to focus on core services growth and data platform scaling. Cash position strong at $10.3M.

#CSBR Champions Oncology Reports Record Quarterly Revenue of $14.0 Million

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

v1s1on_3ndl3ss_

@v1s1on-3ndl3ss.bsky.social

6 months ago

Earnings This Week :

#CODA #HAIN #HYFT #PLAY #CSBR #HITI #FERG #EPM #FLUX #GIS #HTOO #IPHA #MANU #QSG #CBRL #NNDM #SANG #DRI #FDS #FDX #LEN #RSSS #SCHL #BTC

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Champions Oncology Reports Record Annual Revenue of $57 Million Champions Oncology (NASDAQ:CSBR) reported strong financial results for fiscal year 2025, achieving record annual revenue of $57 million, representing a 14% year-over-year increase. The company demonstrated significant profitability improvements with net income of $4.6 million and adjusted EBITDA income of $7.1 million, compared to an adjusted EBITDA loss in the previous year.Key highlights include the successful launch of a high-margin data business generating $4.7 million in data license revenue, improved gross margins reaching 50% (up from 41%), and a strong cash position of $9.8 million with no debt. However, Q4 showed some challenges with revenue declining 12% to $12.3 million and an adjusted EBITDA loss of $1.2 million.

#CSBR Champions Oncology Reports Record Annual Revenue of $57 Million

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Champions Oncology to Reveal Full Year 2025 Performance: Q4 Earnings and Future Outlook Coming July 23 Get comprehensive insights into Champions Oncology's Q4 and full-year 2025 financial performance. Join the earnings call on July 23 for complete analysis. See details.

#CSBR Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Champions Oncology Unveils Game-Changing Radiopharmaceutical Platform: Tests 30+ Cancer Models with 10 Key Isotopes New platform combines 10 radioisotopes with extensive PDX tumor model bank for enhanced oncology drug development. Discover how this expansion transforms cancer research.

#CSBR Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House Champions Oncology (NASDAQ:CSBR) has secured a radioactive materials license, enabling in-house preclinical studies with various radionuclides. This development enhances the company's capabilities in developing and evaluating targeted radiotherapeutics.The license allows Champions to combine radionuclide-based therapeutic testing with their existing patient derived xenograft (PDX) models platform under one roof. The integrated program will support drug developers in various modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.CEO Ronnie Morris emphasized that this license represents a significant milestone in supporting biopharmaceutical partners developing next-generation radiotherapeutics, positioning the company to advance radiopharmaceutical development with enhanced translational precision.

#CSBR Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million Champions Oncology (Nasdaq:CSBR) reported record-breaking financial results for Q3 fiscal 2025. Total revenue increased 42% to $17.0 million, with net income reaching $4.5 million and adjusted EBITDA of $5.2 million.The company achieved several key milestones, including signing their first data licensing deal worth up to $8.0 million and improving operational efficiency. Core services business grew 4%, while gross profit reached $10.4 million with a 61% margin. Year-to-date performance showed 23% revenue growth to $44.6 million.Cost reduction initiatives proved successful, with total costs decreasing by 14.1% to $12.5 million compared to the previous year. The company maintains a strong financial position with $3.2 million cash on hand and no debt, while research services margin improved from 35% to 48% year-over-year.

#CSBR Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Revolutionary Cancer Research Alert: Champions Oncology Unveils 17 Game-Changing Studies at AACR 2025 Champions Oncology advances oncology research with 17 groundbreaking presentations on AI-driven models and innovative drug testing platforms at AACR 2025.

#CSBR Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Champions Oncology Boosts Bioanalytical Services with Cytek Aurora Tech and Key Executive Hire Champions Oncology enhances its bioanalytical capabilities with advanced Cytek Aurora flow cytometers and appoints industry veteran Troy Tremaine to lead commercial strategy.

#CSBR Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Champions Oncology Q2 Earnings Surge: Revenue Soars 17% as Operational Efficiency Drives Profitability Champions Oncology delivers impressive Q2 results with $13.5M revenue, achieves profitability through cost reduction and improved margins. See full earnings breakdown.

#CSBR Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

#investing #StockMarket #news

www.stocktitan.net/news/CSBR/champions-onco...

0 0 0 0